Sprout Health Tirzepatide Review: Cost, Compounded vs Brand & Honest Verdict (2026)

Sprout Health is a LegitScript-certified compounded telehealth program with a low-friction signup and, unusually for a low-cost compounder, a real brand-name Wegovy/Zepbound pathway. Its headline is compounded tirzepatide from $199/month (compounded semaglutide from $149/month). This review covers what Sprout is, what it dispenses, the compounded-versus-brand distinction, its real pricing, and the catches. We disclose an affiliate relationship with Sprout; it never changes our scoring, and every fact here comes from Sprout's own program.

What Sprout Health is

Sprout Health is a telehealth weight program that is LegitScript-certified — a third-party trust signal many compounded startups lack. A licensed prescriber reviews an online intake and, where appropriate, compounded tirzepatide ships from $199/month as a weekly injectable, with compounded semaglutide from $149/month on the same platform. Sprout also offers a genuine brand-name Wegovy/Zepbound pathway for patients who specifically want an FDA-approved product. The signup is deliberately low-friction — often no labs and no separate video visit are required. The trade-offs are real: Sprout does not name a medical director, that low-friction model means thinner clinical oversight, state availability is gated behind a quiz rather than published upfront, and the tirzepatide itself is compounded and not FDA-approved.

The compounded-vs-brand question

Two very different products share the name tirzepatide:

• •Brand tirzepatide is Eli Lilly's FDA-approved Zepbound (weight management, obstructive sleep apnea) and Mounjaro (type 2 diabetes) — the exact molecule and dose studied in the pivotal trials.
• •Compounded tirzepatide is pharmacy-made, not FDA-approved, and was not the product tested in those trials.

Sprout's headline $199/month tirzepatide is compounded, which is why it sits far below brand pricing. That matters more in 2026: the FDA declared the tirzepatide shortage resolved in October 2024, and the enforcement discretion that permitted routine large-scale compounding ended in early 2025 (around February 18, 2025 for 503A pharmacies, March 19, 2025 for 503B outsourcing facilities) — the full timeline is in our guide to whether compounded tirzepatide is still legal in 2026. Sprout's separate brand pathway is for Wegovy/Zepbound; note that Wegovy is semaglutide (a different molecule), while Zepbound is the FDA-approved brand tirzepatide.

What Sprout Health costs in 2026

Sprout publishes compounded pricing from $199/month for compounded tirzepatide and from $149/month for compounded semaglutide. Because the price is quoted as a "from" figure and state availability is quiz-gated, confirm your exact monthly cost and what you will be dispensed during signup. The brand pathway (Wegovy/Zepbound) is a separate, higher-cost route.

For context on the brand tirzepatide drug, LillyDirect sells brand Zepbound self-pay vials at roughly $299–$449/month depending on dose (prices effective February 23, 2026; 28-day supply). Sprout's compounded tirzepatide undercuts that, but you are comparing a non-FDA-approved product to the approved one. For the full cash-price picture, see our Zepbound cost and savings guide.

How the care model holds up

Sprout's strengths are a genuine LegitScript certification, a real brand Wegovy/Zepbound path alongside compounded options, transparent from-$199/month compounded pricing, and a low-friction signup. The trade-offs are the flip side of that convenience: the tirzepatide is compounded and not FDA-approved; there is no named medical director, and the low-friction model (often no labs or visit) means thinner clinical oversight; it is injectable only with no oral pathway; and state availability is quiz-gated rather than published. As with any GLP-1 service, confirm continuity of care and read the cancellation terms; tirzepatide carries labeled warnings for acute pancreatitis, gallbladder disease, and a boxed thyroid C-cell tumor warning — see our guides on Zepbound side effects, the gallbladder risk, and the thyroid cancer warning.

Does the drug work? (Separate from the provider)

Separate the provider from the medication, and the brand molecule from a compounded copy. Brand tirzepatide's efficacy is trial-grade: in the 72-week SURMOUNT-1 trial, adults without diabetes lost on average roughly 15% to 21% of body weight across the 5–15 mg doses, versus about 3% on placebo¹; against semaglutide in SURMOUNT-5, tirzepatide produced significantly greater weight loss — about 20% versus 14%². Those results were established with the brand molecule; compounded versions were never tested in those trials. The full picture is in our tirzepatide evidence guide.

The honest verdict

Sprout Health is a reasonable pick if you want LegitScript-certified compounded tirzepatide with an optional brand path and value a fast, low-friction signup, and you are comfortable with a compounded, non-FDA-approved product. The reservations are the thin clinical oversight that comes with the no-labs/no-visit model, the absence of a named medical director, the injectable-only menu, and quiz-gated state availability. If you want a lower flat price with included nurse/dietitian support, weigh CoreAge Rx; if you specifically want brand tirzepatide, price Zepbound against LillyDirect. See our best tirzepatide providers ranking and best place to get Zepbound online roundup.